AMR | pharmaphorum

Saturday 19 September 2026

AMR

R&D

Bioinfect Conference Liverpool 2025

When is the superbug message going to bite?

As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.

News

Roche takes new antibiotic into phase 3 for 'urgent threat'

Roche takes new antibiotic into phase 3 for 'urgent threat'

Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance.

R&D

a waterfall of pills

Growing threat of AMR: UN calls for urgent global action

In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c

R&D

Interview with James Graham Recce Pharma

LSX 2024 - James Graham, Recce Pharma

A lot of ink has been spilled about the anti-microbial resistance space and why it’s so hard to create a profitable company in it.

Market Access

pop art medicines

Overcoming AMR market failure: Three start-up stories

Slowly but surely, the world’s antibiotics are becoming less effective as disease-causing bacteria evolve into drug-resistant “superbugs”.

R&D

the fight against AMR

AI and the battle against AMR

One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.